Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Emerging Markets expected to grow with new product launches and higher volumes, led by Rest of World and favorable currency movements. The company targets an adjusted EBITDA margin close to 25%, aided by launches, business development, and cost optimization (Page 5).
From Dr Reddys Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Emerging Markets expected to grow with new product launches and higher volumes, led by Rest of World and favorable currency movements.
- India business projected to deliver robust double-digit growth, driven by innovation franchise, new brand launches, price increases, and volume growth.
- US business to grow in double digits ex-lenalidomide, supported by biosimilars, consumer health, and 505(b)(2) products.
- Semaglutide sales expected to reach around 12 million units in FY27, with potential growth also in emerging markets beyond India.
- Biosimilars like abatacept expected to contribute to growth, with break-even targeted post-launch (around FY28).
- Continued focus on launching new products globally (27 new product launches planned in the US for FY27).
2 more points from Dr Reddys Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Dr Reddys Laboratories Ltd said on margins in the Q4 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- The annual capex plan for the next year is around ₹2,000 crores.
- Investment will be largely focused on biosimilars, certain product-specific investments, and general capex.
- Continued strategic investments include partnerships for biologics development to share R&D costs.
- There is potential capacity expansion, e.g., qualifying capacity at FTO11 by FY28 to increase production (possibly up to 40 million units), but current demand does not yet require this.
- Ongoing targeted investments in branded franchises, such as Nicotine Replacement Therapy (NRT) and branded generics, to support long-term growth.
2 more points from Dr Reddys Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Dr Reddys Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹221 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Reddys Laboratories Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
Dr Reddys Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Reddys Laboratories Ltd Q4 FY26 results?
Emerging Markets expected to grow with new product launches and higher volumes, led by Rest of World and favorable currency movements. The company targets an adjusted EBITDA margin close to 25%, aided by launches, business development, and cost optimization (Page 5).
What is Dr Reddys Laboratories Ltd share price analysis?
Dr Reddys Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 31.1 with a market cap of ₹100,161 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Reddys Laboratories Ltd planning capital expenditure?
The annual capex plan for the next year is around ₹2,000 crores.
Keep Dr Reddys Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.